Caspian Journal of Internal Medicine
Babol University of Medical Sciences
Wed, Jan 8, 2025
[Archive]
Volume 11 - Covid 19 Supplement 1
Caspian J Intern Med 2020, 11 - Covid 19 Supplement 1: 583-584 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rismanbaf A. Insomnia drug therapy in COVID-19 patients; a Letter to Editor. Caspian J Intern Med 2020; 11 :583-584
URL: http://caspjim.com/article-1-2251-en.html
URL: http://caspjim.com/article-1-2251-en.html
Department of Clinical Pharmacy and Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran , alirismanbaf74@gmail.com
Abstract: (3972 Views)
Coronavirus disease 2019 (COVID-19) is a highly contagious disease caused by the newly emerging SARS-CoV-2 virus that was first reported in December 2019 and was announced as a pandemic disease on March 11th, according to a World Health Organization (WHO) warning (1). SARS-CoV-2 is mainly transmitted through respiratory droplets and close contact, accordingly, requires treatment in isolation. It has been reported that many patients developed sleep disturbances due to isolation treatment or medication use, which can lead to pathological events and impaired immunity, and need to prescribe hypnotic medications (2). Also, some patients may have taken hypnotic medications before developing COVID-19 and may be dependent on these medications, and now, with the onset of COVID-19 and the addition of new drugs for its treatment, they need to change their hypnotic medications.
Type of Study: Letter to Editor |
Subject:
psychiatry
Received: 2020/03/21 | Accepted: 2020/10/19 | Published: 2017/07/15
Received: 2020/03/21 | Accepted: 2020/10/19 | Published: 2017/07/15
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
